Phase 1 N=11 Aspirin Prophylaxis in Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Serious Adverse Events — 6; 9; 0; 0 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject
Insomnia
Primary: Area Under the Concentration-Time Curve (AUC) for LY2624803 and the Metabolite LSN2797276 — 5240; 3340; 4620; 192 nanogram*hour per milliliter (ng*h/mL)
Phase 1 N=28 Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban
Therapeutic Equivalency
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC) Incl. Bioequivalence (BE) Evaluation — 1374; 1268 µg*hr/L…
Phase 1 N=15 Phase I Clinical Study of E7389
Cancer
Primary: Number of Subjects Who Experienced Dose Limiting Toxicity (DLT) — 5 participants
Phase 1 N=32 Study of E7389 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Determination of the Maximum Tolerated Dose — 1.0 mg/m^2
Phase 1 N=44 Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects
Healthy
Primary: Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage® — 739; 753 Nanograms per milliliter (ng/mL)
Phase 1 N=15 Anidulafungin PK in Infants and Toddlers
Invasive Fungal Infections
Primary: The Pharmacokinetics (Area Under the Curve) of Anidulafungin in Infants and Toddlers Less Than 24 Months of Age With Suspected Serious Infection. — 84 µg*h/mL
Phase 1 N=26 A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia
Healthy
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 21380.0; 21370.0 ng*hr/mL
Phase 1 N=80 Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate — 49.06; 0; 49.84; 50.77 ng/ml
Phase 1 N=24 Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
Thrombosis · Heparin-induced Thrombocytopenia
Primary: Number of Abnormal Lab Results Resulting in Adverse Events. — 0 Adverse Events
Phase 1 N=30 Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration
Healthy
Primary: AUC0-t — 1139.3; 1115.6; 1065.3 μg*hr/mL
Phase 1 N=83 Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)
Atherosclerotic Vascular Disease
Primary: Percent Reduction From Baseline in TBRmeanmax of the Qualifying Segment — 1.4; 5.8 Percent reduction — p=0.006
Phase 1 N=18 A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066
Healthy
Primary: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib — 1423; 3806; 6569 ng*hr/mL
Phase 1 N=12 Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Tarceva Maximum Tolerated Dose in mg — 150 mg
Phase 1 N=51 Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)
Healthy
Primary: Geometric Mean Fold-rise (GMFR) After the Administration of the Lyophilized Formulation of V710 (60 mcg). — 5.3; 1.0 Ratio